Clinical trials of the Kazakh vaccine are conducted in accordance with the Order of the Minister of Health of the Republic of Kazakhstan dated December 11, 2020 No. KR DSM-248/2020, where all participants in clinical trials are insured under a voluntary Insurance Contract according to the Rules and Regulations of insurance companies in case of an insured event. At the same time, the amount of insurance payments and the terms of insurance are information of a closed nature for third parties under the terms of insurance.
Information about the progress of clinical trials and other information, as well as the amount of insurance payments are confidential information.
In accordance with international requirements, the volunteers signed an informed consent to participate in a clinical trial and an obligation of confidentiality of information. In this regard, the journalist could not get this information from the volunteer.
At the same time, long-term studies and the results of phase 1-2 clinical trials and preliminary results of phase 3 studies show the safety of the vaccine for humans and the absence of adverse events for the 18+ age group.